RT Journal Article
SR Electronic
T1 DGI-055 Protease Inhibitors: New Drugs For Treatment of Chronic Hepatis C
JF European Journal of Hospital Pharmacy: Science and Practice
JO Eur J Hosp Pharm
FD British Medical Journal Publishing Group
SP A115
OP A116
DO 10.1136/ejhpharm-2013-000276.321
VO 20
IS Suppl 1
A1 M Pérez Abánades
A1 C Martínez Nieto
A1 E Alañón Plaza
A1 A Aranguren Oyarzábal
A1 E Deben Tiscar
A1 E Ramírez Herráiz
A1 T Gallego Aranda
A1 A Ibañez Zurriaga
A1 A Morell Baladrón
YR 2013
UL http://ejhp.bmj.com/content/20/Suppl_1/A115.2.abstract
AB Background The protease inhibitors boceprevir and telaprevir are indicated for treatment of chronic hepatitis C (CHC) genotype 1 in combination with peginterferon-alfa and ribavirin. These drugs increase efficacy and adverse effects. Purpose To study the effectiveness and safety of boceprevir and telaprevir for treatment of CHC. Materials and Methods Retrospective observational study including all patients who started treatment with telaprevir or boceprevir for treatment of CHC from January to September 2012. Collected data: age, sex, type of patient (treatment-naive, recurrent or non-responder), liver fibrosis, HIV coinfection, viral loads at weeks 0, 4, 8, 12, 24 to evaluate efficacy and adverse effects and supportive treatment to evaluate safety. View this table:Abstract DGI-055 Table 1 Baseline characteristics View this table:Abstract DGI-055 Table 2 Efficacy and safety Results We included 51 patients, 35 (70%) men and 15 (30%) women, with a mean age of 51 years. 5 patients were co-infected with HIV (off-label use). Conclusions Most patients had grade 3–4 liver fibrosis. Most patients were recurrent or non-responders to previous treatment. Telaprevir was the most used protease inhibitor. Patients using telaprevir got negative viral loads before patients using boceprevir. A high percentage of patients using boceprevir required the dose of peginterferon-alfa to be reduced and treatment with G-CSF due to neutropenia. No conflict of interest.